Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abelacimab vs Apixaban in Cancer-Associated VTE (ASTER)
NCT05171049Phase 3Terminated
- Sponsor
- Anthos Therapeutics
- Start
- May 2022
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of abelacimab in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE), sponsored by Anthos Therapeutics. Primary endpoint: Time to first event of centrally adjudicated VTE recurrence at 6 months. Started May 2022; status: terminated.
02
Drugs
abelacimab
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT05171049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171049.